Incyte Corp

Company facts

Industry

Services-Commercial Physical & Biological Research

Headquarters

Wilmington, Delaware

Most recent report

10-Q, filed Oct 29, 2026

Incorporated

Delaware

Filings on record

1,004+ filings

On EDGAR

CIK 879169

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 10 sections worth reading, with 1 positive, 11 notable, and 4 negative flags.

• Financial Statements (Item 1)

  Massive $1.23B Vega acquisition charge, $246M CMS settlement, and a net loss of $785M in Q3 2026.
  Notable

  • Customer concentration: top five customers made up 59% of accounts receivable at Sept 30, 2026.
  • Recorded a $246M one-time non-cash benefit in Q2 2026 from CMS settlement reversing OPZELURA line extension accruals.

• Management's Discussion (Item 2)

  Net loss of $784.8M in Q3 2026 vs net income of $424.2M in Q3 2025; $1.23B Vega IPR&D charge.
  Positive

  • Cash, equivalents and marketable securities of $3.9B at Sept 30, 2026; no borrowings on $500M credit facility.
  Notable

  • Vega acquisition completed July 2026; latarcibart in Phase 3 for von Willebrand disease; $1.23B IPR&D charge.
  • Povorcitinib NDA for HS accepted by FDA; EU CHMP positive opinion; potential US approval in Q1 2027.
  • OPZELURA net sales include $246.0M one-time non-cash benefit from CMS settlement reversing prior accruals.
  • JAKAFI net sales up 4% to $826.5M in Q3 2026; volume up $102.8M offset by price decrease of $67.4M.
  • Novartis royalty dispute settled: paid $280M, reduced future JAKAFI royalty rate by 50% from Jan 1, 2025.
  • $1.23 billion Vega IPR&D expense in Q3 2026; non-deductible for tax, unfavorably impacting effective tax rate.
  • Operating cash flow fell to $201.7M for nine months 2026 from $870.2M, due to Vega cash consideration.
  Negative

  • Net loss of $784.8M in Q3 2026 vs net income of $424.2M in Q3 2025; $1.23B Vega charge drove the swing.

• Risk Factors (Item 1A)

  Company-specific patent challenges, IRA impact, and JAKAFI concentration quantified.
  Notable

  • ORPHAN Cures Act extended timeline for Medicare price negotiation on ruxolitinib phosphate, but future policy could change.
  • May 2025 executive order directs HHS to establish 'most favored nation' price targets for certain drugs.
  Negative

  • Company depends on a limited number of specialty pharmacies and wholesalers for most product revenue.
  • Multiple generic manufacturers have filed ANDAs challenging JAKAFI patents expiring June and December 2028.
  • OPZELURA also faces generic ANDA challenges from four manufacturers on patents expiring 2031 and 2040.

What changed: Sep 2026 vs. Jun 2026

About 3% of INCY's Sep 2026 10-Q is new information. 21 paragraphs were added, 159 changed, and 25 removed. Below are the most important lines SECSift identified.

• Item 1 67
• Item 2 59
• Item 1A 9
• Item 5 5
• Item 6 3
• Item 3 1
• Item 4 1